Kite Pharma Inc. (Nasda: KITE) reported positive results from a primary analysis of ZUMA-1 for axicabtagene ciloleucel to treat chemorefractory aggressive B-cell non-Hodgkin lymphoma. Shares of the biopharmaceutical leaped $13.94 to close at $70.77.
Positive results for Kite Pharma
February 28, 2017 at 19:31 PM EST
